# BAY3401016; Biomarker Study Alport

> **NCT07211685** · PHASE2 · RECRUITING · sponsor: **Bayer** · enrollment: 60 (estimated)

## Conditions studied

- Alport Syndrome

## Interventions

- **BIOLOGICAL:** BAY 3401016
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07211685
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-19
- **Primary completion:** 2028-07-27
- **Final completion:** 2028-07-27
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07211685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07211685, "BAY3401016; Biomarker Study Alport". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07211685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*